Skip to Content
Merck
  • Comparison of intralesional corticosteroid and propranolol treatment of periorbital infantile hemangiomas: an outcome study of 61 cases.

Comparison of intralesional corticosteroid and propranolol treatment of periorbital infantile hemangiomas: an outcome study of 61 cases.

European journal of ophthalmology (2014-04-15)
Marije J Hoornweg, Peerooz Saeed, Michael W T Tanck, J Joris Hage, Adriaan D Coumou, Chantal M A M Van Der Horst
ABSTRACT

To compare intralesional corticosteroid (IC) injections with oral propranolol in children with periorbital infantile hemangioma (IH). Children were diagnosed with IH and treated with IC (n = 29) or propranolol (n = 14). In cases in which no further improvement was seen, treatment was stopped and the outcome measured. Type, duration, and complications of treatment and supportive or additional therapies were scored, along with outcomes of visual measurements, at the start and end of therapy. Twenty-one of the 29 children (72%) treated with IC injections were given a second injection and 16 (55%) were given more than two. Median duration of IC therapy was 15.9 months (interquartile range (IQR) 10.28), compared with 6.5 months (IQR 4.87) for propranolol (p<0.001). The complications reported after IC injections were bleeding (n = 9) and ulceration (n = 7). No complications were noted in the propranolol group. Additional therapy consisting of oral prednisolone therapy was applied in one child from the steroid-treated group. The levels of amblyopia and the median absolute improvement did not significantly differ between the groups. The IC injections and oral propranolol medication equally improved amblyopia in children with IH of the periorbital and cheek region; however, propranolol was associated with fewer complications and additional or supportive treatment was not indicated. We prefer oral propranolol medication over IC injections in cases in which IH threatens to hamper visual acuity.

MATERIALS
Product Number
Brand
Product Description

Cyclopentolate for system suitability, European Pharmacopoeia (EP) Reference Standard
Methylprednisolone, European Pharmacopoeia (EP) Reference Standard
USP
Methylprednisolone, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
6α-Methylprednisolone, ≥98%
Cyclopentolate hydrochloride, European Pharmacopoeia (EP) Reference Standard